IART (Integra Lifesciences Holdings) Cyclically Adjusted Revenue per Share: $21.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IART Integra Lifesciences Holdings Corp IART
71 GF Score
Price $17.24
GF Value $20.57
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings Cyclically Adjusted Revenue per Share?

Integra Lifesciences Holdings IART +0.94% 71 Cyclically Adjusted Revenue per Share is $21.51 as of Jun. 2026. GuruFocus rates IART with a GF Score™ of 71/100 and a GF Value™ of $20.57 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Integra Lifesciences Holdings's adjusted revenue per share for the three months ended in Jun. 2026 was $5.357. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $21.51 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Integra Lifesciences Holdings's average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Integra Lifesciences Holdings was 33.00% per year. The lowest was 4.10% per year. And the median was 7.50% per year.

As of today (2026-08-08), Integra Lifesciences Holdings's current stock price is $17.243. Integra Lifesciences Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $21.51. Integra Lifesciences Holdings's Cyclically Adjusted PS Ratio of today is 0.80.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Integra Lifesciences Holdings was 4.78. The lowest was 0.43. And the median was 3.23.


Integra Lifesciences Holdings  (NAS:IART) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Integra Lifesciences Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.243/21.51
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Integra Lifesciences Holdings was 4.78. The lowest was 0.43. And the median was 3.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Integra Lifesciences Holdings Cyclically Adjusted Revenue per Share Related Terms


Integra Lifesciences Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Integra Lifesciences Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integra Lifesciences Holdings Cyclically Adjusted Revenue per Share Chart

Integra Lifesciences Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.82 17.90 18.81 19.71 20.70

Integra Lifesciences Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.35 20.58 20.70 21.18 21.51

IART vs ENOV, AHCO, INSP: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Cyclically Adjusted PS Ratio falls into.


IART
71GF Score
Integra Lifesciences Holdings Corp IART
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integra Lifesciences Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Integra Lifesciences Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.357/333.9520*333.9520
=5.357

Current CPI (Jun. 2026) = 333.9520.

Integra Lifesciences Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.089 241.428 4.273
201612 3.181 241.432 4.400
201703 3.299 243.801 4.519
201706 3.573 244.955 4.871
201709 3.509 246.819 4.748
201712 4.633 246.524 6.276
201803 4.473 249.554 5.986
201806 4.385 251.989 5.811
201809 4.239 252.439 5.608
201812 4.428 251.233 5.886
201903 4.170 254.202 5.478
201906 4.448 256.143 5.799
201909 4.424 256.759 5.754
201912 4.582 256.974 5.955
202003 4.125 258.115 5.337
202006 3.054 257.797 3.956
202009 4.368 260.280 5.604
202012 4.572 260.474 5.862
202103 4.223 264.877 5.324
202106 4.570 271.696 5.617
202109 4.527 274.310 5.511
202112 4.728 278.802 5.663
202203 4.469 287.504 5.191
202206 4.757 296.311 5.361
202209 4.619 296.808 5.197
202212 4.759 296.797 5.355
202303 4.626 301.836 5.118
202306 4.698 305.109 5.142
202309 4.792 307.789 5.199
202312 5.089 306.746 5.540
202403 4.745 312.332 5.073
202406 5.402 314.175 5.742
202409 4.982 315.301 5.277
202412 5.790 315.605 6.127
202503 5.004 319.799 5.225
202506 5.419 322.561 5.610
202509 5.238 324.800 5.386
202512 5.665 324.054 5.838
202603 5.093 330.213 5.151
202606 5.357 333.952 5.357

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $21.51 mean?
Integra Lifesciences Holdings (IART) has a Cyclically Adjusted Revenue per Share of $21.51 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Integra Lifesciences Holdings and its competitors.
Is Integra Lifesciences Holdings' Cyclically Adjusted Revenue per Share too high?
Integra Lifesciences Holdings' current Cyclically Adjusted Revenue per Share is $21.51. Overall, Integra Lifesciences Holdings has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Cyclically Adjusted Revenue per Share compare to ENOV and AHCO?
Integra Lifesciences Holdings' Cyclically Adjusted Revenue per Share of $21.51 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Integra Lifesciences Holdings and its competitors. Integra Lifesciences Holdings's current Cyclically Adjusted Revenue per Share is $21.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.57, compared to a current price of $17.24 — trading 16.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $21.51. Integra Lifesciences Holdings' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current Cyclically Adjusted Revenue per Share is $21.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integra Lifesciences Holdings (IART) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of $17.24 is trading 16.2% below its estimated GF Value™ of $20.57. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for IART:

  • Cyclically Adjusted Revenue per Share: $21.51
  • GF Value™: $20.57 vs. price of $17.24 (16.2% below fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integra Lifesciences Holdings Business Description

Other Exchanges IL3:Germany
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
71GF Score

Get the complete analysis for IART

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.24
Price
$20.57
GF Value